-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Exagen, Lowers Price Target to $10

Benzinga·03/11/2026 17:40:31
Listen to the news
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $15 to $10.